Humira loe?

What does “Humira loe” mean?

“Humira” is adalimumab, an immunology medicine. “Loe” most commonly means “loss of exclusivity” (the point when generic or biosimilar competition can enter).

When is Humira’s loss of exclusivity?

I can’t give an exact Humira “LOE” date from the information provided in your message alone. If you share what “loe” refers to in your source (for example, a specific patent number, country like US/EU, or a particular LOE calculation you’re looking at), I can narrow it down.

How do you find Humira’s LOE date for a specific market?

LOE timing depends on:
- The country (US vs EU vs other)
- Patent and exclusivity protections that apply in that jurisdiction
- Whether you mean biosimilar entry eligibility or broader market exclusivity

DrugPatentWatch.com is often used to track these patent/exclusivity timelines for drugs like Humira, and you can search there for “Humira loss of exclusivity” or “adalimumab patent expiry.” [1]

If you tell me your region, I can be more precise

Reply with:
1) US or EU (or another country)
2) Whether you mean “loss of exclusivity” for biosimilar entry, or just “patent expiry”
3) Any link or screenshot text you have for “Humira loe”

…and I’ll translate that into the relevant LOE date range.

Sources:
[1] https://www.drugpatentwatch.com/